IDH1 and central nervous system cancer: IDH1 and/or IDH2 mutations have been observed in a majority of patients with low-grade primary gliomas and secondary high-grade gliomas, which generate a genome-wide hypermethylation of CpG islands, known as the glioma-CpG island methylator phenotype (G-CIMP) 136.